MK-3120 Clinical Trials
4 recruitingBiologic
Phase 14Phase 24
Showing 1–4 of 4 trials
Recruiting
Phase 1Phase 2
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Urothelial Carcinoma
Merck Sharp & Dohme LLC48 enrolled28 locationsNCT05562830
Recruiting
Phase 1Phase 2
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Bladder Cancer
Merck Sharp & Dohme LLC55 enrolled14 locationsNCT07232602
Recruiting
Phase 1Phase 2
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Urinary Bladder NeoplasmsBladder Cancer
Merck Sharp & Dohme LLC45 enrolled14 locationsNCT07222488
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Advanced Solid TumorsMalignant Neoplasm
Merck Sharp & Dohme LLC270 enrolled42 locationsNCT06818643